Previous 10 | Next 10 |
Image source: The Motley Fool. Puma Biotechnology Inc (NASDAQ: PBYI) Q4 2019 Earnings Call Feb 20, 2020 , 4:30 p.m. ET Operator Continue reading
Puma Biotechnology, Inc. (PBYI) Q4 2019 Earnings Conference Call February 20, 2020 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chief Executive Officer, President & Chairman Maximo Nougues - Chief Financial Officer ...
Puma Biotechnology (NASDAQ: PBYI ): Q4 Non-GAAP EPS of $0.01 beats by $0.27 ; GAAP EPS of -$0.29 beats by $0.19 . Revenue of $62.9M (-11.5% Y/Y) beats by $2.94M . Press Release More news on: Puma Biotechnology, Inc., Earnings news and commentary, Healthcare stocks news,
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2019. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2019, compared to the fourth quarter and full year 2018....
Picking home-run stocks -- or stocks capable of generating exponential returns on capital -- is no easy matter. That being said, there has arguably never been a more favorable environment for risk-tolerant investors on the hunt for unusual growth opportunities. The fact of the matter is t...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 20, 2020, following release of its fourth quarter and full year 2019 financial results. The call may be accessed by dialing 1-877-709-8150...
Gainers: Myomo (NYSEMKT: MYO ) +98% . More news on: Myomo, Inc., VIVUS, Inc., Predictive Oncology Inc., Stocks on the move, , Read more ...
Shares of Puma Biotechnology (NASDAQ: PBYI) , a small-cap cancer company, are absolutely on fire this morning. Specifically, the biotech's shares gained as much as 38% right out of the gate Wednesday. Puma's shares are still up by a healthy 32% as of 9:46 a.m. EST. What's driving this eye-po...
February 5, 2020 Palm Beach, FL –February 5, 2020 – Acute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute myeloid leukemia (AML) at many medical centers, university hospitals, an...
Company Overview Puma Biotechnology ( PBYI ) is a pharmaceutical company producing drugs used in cancer treatments. Their main product is Nerylinx, a compound used to treat breast cancer, specifically those that are HER-2 positive. The company has seen much volatility in terms of earning...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...